Aclaris Therapeutics, Inc. (ACRS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$6.17+3.70%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ACRS
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||
| Revenues | 8.2 | 7.8 | 18.7 | 31.2 | 29.8 | 6.8 | 6.5 | 4.2 | 6.2 | 1.7 | — | — |
| Total Revenues | — | — | — | — | — | — | — | — | — | 1.7 | — | — |
| Cost of Revenues | 1.7 | 2.1 | 2.8 | 3.4 | 4.0 | 4.7 | 5.1 | 4.1 | 4.3 | 1.2 | — | — |
| Gross Profit | — | — | — | — | — | — | — | — | 3.2 | 0.5 | — | — |
| Operating Expenses & Income | ||||||||||||
| R&D Expenses | 63.3 | 52.6 | 33.6 | 98.4 | 77.8 | 43.8 | 29.3 | 64.2 | 60.8 | 35.8 | 33.5 | 15.3 |
| Operating Income | (86.3) | (76.4) | (141.9) | (97.4) | (89.9) | (89.7) | (50.9) | (111.1) | (84.8) | (54.4) | (48.6) | (20.7) |
| Earnings from Continuing Operations | ||||||||||||
| Interest & Investment Income | 6.7 | 7.6 | 8.0 | 8.5 | — | — | — | — | — | — | — | 0.1 |
| Other Non-Operating Income / Expenses | 10.6 | 11.5 | 9.9 | 8.5 | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | — | (64.9) | (132.1) | (88.8) | (86.9) | (90.9) | (51.2) | (113.5) | (82.1) | (70.4) | (48.1) | — |
| Income Tax Expense | — | — | — | (0.4) | — | — | (0.2) | (1.8) | (1.8) | (1.8) | — | — |
| Net Income | ||||||||||||
| Net Income | (75.7) | (64.9) | (132.1) | (88.5) | (86.9) | (90.9) | (51.0) | (161.4) | (132.7) | (68.5) | (48.1) | (20.6) |
| Per Share | ||||||||||||
| Basic EPS | (0.53) | (0.53) | (1.71) | (1.27) | (1.33) | (1.60) | (1.20) | — | — | — | — | — |
| Diluted EPS | (0.53) | (0.53) | (1.71) | (1.27) | (1.33) | (1.60) | (1.20) | — | — | — | — | — |
| Revenue per Share | 0.06 | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 142.7 | 122.6 | 77.3 | 69.8 | 65.2 | 56.7 | 42.5 | — | — | — | — | — |
| Diluted Weighted Avg Shares | 142.7 | 122.6 | 77.3 | 69.8 | 65.2 | 56.7 | 42.5 | — | — | — | — | — |
| Supplemental | ||||||||||||
| EBITDA | — | (75.9) | (141.1) | (96.5) | (89.1) | (88.8) | (49.6) | (104.6) | (82.9) | (54.0) | — | — |
| EBIT | (86.3) | (76.4) | (141.9) | (97.4) | (89.9) | (89.7) | (50.9) | (111.1) | (84.8) | (54.4) | (48.6) | (20.7) |
| Effective Tax Rate | — | — | — | 0.4% | — | — | 0.4% | 1.6% | 2.2% | 2.6% | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.